gatifloxacin has been researched along with Bacterial Conjunctivitides in 10 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the safety and efficacy of black tea extract in the treatment of bacterial conjunctivitis in a rabbit model and compare it with that of gatifloxacin drops." | 4.31 | Safety and Efficacy of Black Tea Extract in the Treatment of Acute Bacterial Conjunctivitis: A Rabbit Model. ( Abdullatif, AM; Hassan, LM; Marrie, A; Shash, RY, 2023) |
| " Safety variables included adverse events (AEs), lisamine green, fluorescein ocular surface stains, and clinical signs of tolerability." | 2.87 | Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. ( Baiza-Durán, L; Casillas-Magallanes, M; Gómez-Bastar, PA; González-Lomelí, M; Lizárraga-Corona, A; Mercado-Sesma, AR; Montoya-Sánchez, IM; Mora-González, A; Ochoa-Tabares, JC; Olvera-Montaño, O; Oregon-Miranda, AA; Orozco-Carroll, M; Páez-Garza, JH; Pérez-Balbuena, AL; Sandoval-Delgadillo, LI; Saucedo-Rodríguez, LR; Villanueva-Najera, MA, 2018) |
| "Gatifloxacin is an effective antibacterial drug." | 2.87 | Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis. ( Feng, J; Xu, J, 2018) |
| "The gatifloxacin eye drop has a good therapeutic effect to the bacterial conjunctivitis." | 2.75 | [Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes]. ( Gong, L; Qiu, XD; Qu, J; Sun, XH; Xiong, QC; Yuan, ZL; Zhang, YQ, 2010) |
| " Safety was determined through recording of adverse events." | 2.71 | A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. ( Bernstein, P; Jensen, H; Schiffman, R; Tepedino, M; Whitcup, SM; Yee, RW, 2005) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullatif, AM | 1 |
| Hassan, LM | 1 |
| Shash, RY | 1 |
| Marrie, A | 1 |
| Baiza-Durán, L | 1 |
| Olvera-Montaño, O | 1 |
| Mercado-Sesma, AR | 1 |
| Oregon-Miranda, AA | 1 |
| Lizárraga-Corona, A | 1 |
| Ochoa-Tabares, JC | 1 |
| Pérez-Balbuena, AL | 1 |
| Montoya-Sánchez, IM | 1 |
| Saucedo-Rodríguez, LR | 1 |
| Mora-González, A | 1 |
| Gómez-Bastar, PA | 1 |
| Villanueva-Najera, MA | 1 |
| Sandoval-Delgadillo, LI | 1 |
| González-Lomelí, M | 1 |
| Páez-Garza, JH | 1 |
| Orozco-Carroll, M | 1 |
| Casillas-Magallanes, M | 1 |
| Xu, J | 1 |
| Feng, J | 1 |
| Heller, W | 1 |
| Cruz, M | 1 |
| Bhagat, YR | 1 |
| De Leon, JM | 1 |
| Felix, C | 1 |
| Villanueva, L | 1 |
| Hollander, DA | 1 |
| Jensen, H | 2 |
| Sanfilippo, CM | 1 |
| Allaire, CM | 1 |
| DeCory, HH | 1 |
| Proksch, JW | 1 |
| Ward, KW | 1 |
| Gong, L | 1 |
| Sun, XH | 1 |
| Qiu, XD | 1 |
| Zhang, YQ | 1 |
| Qu, J | 1 |
| Yuan, ZL | 1 |
| Xiong, QC | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Yee, RW | 1 |
| Tepedino, M | 1 |
| Bernstein, P | 1 |
| Schiffman, R | 1 |
| Whitcup, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00518089] | Phase 3 | 859 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [NCT00509873] | Phase 3 | 578 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (NCT00518089)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 59.6 |
| Placebo Eye Drops | 46.7 |
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 51.8 |
| Placebo Eye Drops | 41.3 |
Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye. (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 97.0 |
| Placebo Eye Drops | 92.2 |
Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis. (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 92.8 |
| Placebo Eye Drops | 88.6 |
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture). (NCT00518089)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 92.2 |
| Placebo Eye Drops | 80.2 |
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 74.9 |
| Placebo Eye Drops | 65.2 |
"Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (Note: The Up to Day 6 analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point)." (NCT00509873)
Timeframe: 6 Days
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 64.1 |
| Placebo Eye Drops | 50.0 |
Percentage of patients with clinical improvement of ocular signs at Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus),with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye. (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 97.0 |
| Placebo Eye Drops | 96.2 |
Percentage of patients with clinical improvement of ocular symptoms at Day 6, defined as a decrease (improvement) from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 85.5 |
| Placebo Eye Drops | 82.2 |
Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated (or absent) at Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture) (NCT00509873)
Timeframe: Day 6
| Intervention | Percentage of Patients (Number) |
|---|---|
| Gatifloxacin 0.5% Eye Drops | 89.2 |
| Placebo Eye Drops | 61.4 |
6 trials available for gatifloxacin and Bacterial Conjunctivitides
| Article | Year |
|---|---|
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Conjunct | 2018 |
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis.
Topics: Adolescent; Adult; Aged; Conjunctivitis, Bacterial; Double-Blind Method; Female; Gatifloxacin; Human | 2018 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Pres | 2014 |
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Topics: Anti-Bacterial Agents; Azepines; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquino | 2017 |
[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
Topics: Adolescent; Adult; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Gatiflo | 2010 |
A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.
Topics: Acute Disease; Administration, Oral; Adult; Conjunctivitis, Bacterial; Female; Fluoroquinolones; Gat | 2005 |
4 other studies available for gatifloxacin and Bacterial Conjunctivitides
| Article | Year |
|---|---|
Safety and Efficacy of Black Tea Extract in the Treatment of Acute Bacterial Conjunctivitis: A Rabbit Model.
Topics: Animals; Anti-Bacterial Agents; Conjunctivitis; Conjunctivitis, Bacterial; Fluoroquinolones; Gatiflo | 2023 |
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Conjunct | 2010 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
Topics: Adult; Aza Compounds; Child; Conjunctivitis, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Huma | 2004 |